Skip to content

Preferred Stock at other companies

Biogen logo
BiogenBIIB
$0
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$0

Other financials

Income statement

See full
Revenue--100%
Operating income-$105.9M-41.7%
Net income-$92.6M-33.6%
EPS (diluted)-$3.20+2.7%

Balance sheet

See full
Cash & equivalents$536.7M+223%
Total debt$1.4M+31.3%
Total equity$1.4B+221%
Total assets$1.5B+205%

Cash flow

See full
Operating cash flow-$86.2M-62.5%
CapEx$62.0K
Free cash flow-$86.2M-62.6%

Valuation

See full
Market cap$7.87B+1,075%
Enterprise value$7.34B+1,309%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-35.3%-10.9pp
Debt / equity0.0×
Current ratio15.9×+7.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s preferred stock?
Praxis Precision Medicines, Inc. (PRAX) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
The value of equity shares that have priority over common stock.
How do you interpret preferred stock?
The presence of preferred stock indicates a specific financing strategy, often involving venture capital or structured debt-like equity.
How does preferred stock compare across companies?
Common in early-stage biotech companies as a mechanism for raising capital from institutional investors.